HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Relay Therapeutics and increased the price target from $18 to $19, indicating positive sentiment from the analyst.
September 16, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Relay Therapeutics and increased the price target from $18 to $19, suggesting a positive outlook for the stock.
The analyst's decision to maintain a Buy rating and raise the price target indicates confidence in Relay Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100